Myokardia Inc (NASDAQ:MYOK) insider Joseph Lambing sold 5,000 shares of the firm’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider now owns 95,846 shares in the company, valued at approximately $4,792,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Myokardia Inc (NASDAQ MYOK) opened at $52.60 on Thursday. Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $54.00. The firm has a market cap of $1,858.53, a price-to-earnings ratio of -69.21 and a beta of 4.21.

Myokardia (NASDAQ:MYOK) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.42). Myokardia had a negative net margin of 53.49% and a negative return on equity of 14.92%. The firm had revenue of $5.63 million for the quarter, compared to the consensus estimate of $6.10 million. During the same quarter in the previous year, the company earned ($0.35) earnings per share. The business’s revenue was up 58.6% compared to the same quarter last year. equities research analysts expect that Myokardia Inc will post -1.62 earnings per share for the current fiscal year.

MYOK has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Myokardia from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine downgraded shares of Myokardia from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Wedbush reiterated an “outperform” rating and set a $51.00 price target on shares of Myokardia in a research note on Wednesday, September 20th. TheStreet downgraded shares of Myokardia from a “c” rating to a “d+” rating in a research note on Friday, November 3rd. Finally, BidaskClub upgraded shares of Myokardia from a “sell” rating to a “hold” rating in a research note on Tuesday, December 26th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $54.83.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in Myokardia by 2.5% during the second quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock worth $243,000 after buying an additional 455 shares in the last quarter. American International Group Inc. boosted its stake in Myokardia by 18.8% during the third quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock worth $546,000 after buying an additional 2,018 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Myokardia by 12.4% during the third quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after acquiring an additional 2,299 shares during the period. Nationwide Fund Advisors lifted its holdings in shares of Myokardia by 36.3% during the second quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 2,591 shares during the period. Finally, Hershey Trust Co. lifted its holdings in shares of Myokardia by 26.0% during the third quarter. Hershey Trust Co. now owns 20,064 shares of the biotechnology company’s stock valued at $860,000 after acquiring an additional 4,145 shares during the period. Hedge funds and other institutional investors own 63.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://theolympiareport.com/2018/01/18/joseph-lambing-sells-5000-shares-of-myokardia-inc-myok-stock.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.